- Home
- STAI vs CVKD Comparison
STAI vs CVKD Comparison
Compare STAI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- CVKD
- Stock Information
- Founded
- STAI 2011
- CVKD 2022
- Country
- STAI United States
- CVKD United States
- Employees
- STAI N/A
- CVKD N/A
- Industry
- STAI
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- STAI
- CVKD Health Care
- Exchange
- STAI Nasdaq
- CVKD Nasdaq
- Market Cap
- STAI 24.6M
- CVKD 27.0M
- IPO Year
- STAI N/A
- CVKD 2023
- Fundamental
- Price
- STAI $0.46
- CVKD $13.49
- Analyst Decision
- STAI
- CVKD Strong Buy
- Analyst Count
- STAI 0
- CVKD 1
- Target Price
- STAI N/A
- CVKD $32.00
- AVG Volume (30 Days)
- STAI 14.9M
- CVKD 25.3K
- Earning Date
- STAI 09-17-2025
- CVKD 11-07-2025
- Dividend Yield
- STAI N/A
- CVKD N/A
- EPS Growth
- STAI N/A
- CVKD N/A
- EPS
- STAI N/A
- CVKD N/A
- Revenue
- STAI $1,249,524.00
- CVKD N/A
- Revenue This Year
- STAI N/A
- CVKD N/A
- Revenue Next Year
- STAI N/A
- CVKD N/A
- P/E Ratio
- STAI N/A
- CVKD N/A
- Revenue Growth
- STAI 139.30
- CVKD N/A
- 52 Week Low
- STAI $0.35
- CVKD $8.74
- 52 Week High
- STAI $9.07
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- STAI 44.37
- CVKD 50.95
- Support Level
- STAI $0.48
- CVKD $12.71
- Resistance Level
- STAI $0.73
- CVKD $13.75
- Average True Range (ATR)
- STAI 0.07
- CVKD 0.78
- MACD
- STAI -0.01
- CVKD -0.04
- Stochastic Oscillator
- STAI 2.07
- CVKD 61.61
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.